查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046130

糖尿病胃排空排放治療市場－全球產業規模、佔有率、趨勢、機會與預測：按類型分類，2021-2031年

Diabetic Gastroparesis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Grade 2, Grade 3, By Drug Class, By Route of Administration, By Distribution Channel By Region & Competition), 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球糖尿病胃麻痺治療市場預計將從 2025 年的 30.3 億美元成長到 2031 年的 37.4 億美元，複合年成長率為 3.57%。

該市場涵蓋藥物療法，例如用於治療糖尿病患者胃排空延遲的胃腸排放增強劑和止吐藥，以及外科醫療設備和手術。推動這一成長的主要因素是全球糖尿病盛行率的不斷上升，進而導致需要有效症狀管理的胃腸道疾病發生率增加。例如，根據國際糖尿病聯盟 (IDF) 2024 年的報告，全球約有 5.89 億成年人患有糖尿病，這是大規模的患者群體，極易出現這些長期併發症。

市場概覽
預測期 2027-2031
市場規模：2025年 30.3億美元
市場規模：2031年 37.4億美元
複合年成長率：2026-2031年 3.57%
成長最快的細分市場 網路藥房
最大的市場 北美洲

然而，對藥品安全性和有效性的嚴格監管環境為市場成長帶來了巨大障礙。許多現有治療方法都存在嚴重的副作用，迫使監管機構對新藥和現有藥物都採用嚴格的臨床試驗標準並發布安全警告。這種嚴格的監管構成了市場准入的主要障礙，延長了產品研發週期，並限制了創新療法的核准。因此，醫療專業人員和患者可選擇的治療方案十分有限。

市場促進因素

推動市場發展的關鍵因素之一是強大的臨床研發管線和新型療法的持續開發，這主要得益於製藥公司致力於開發更安全、取代傳統促動力藥的藥物。製造商正集中精力開發新型化學物質 (NCE)，以降低甲氧氯普胺等老藥相關的心血管和神經系統風險，從而解決長期存在的監管安全挑戰。 CinDome Pharma 於 2024 年 5 月宣布完成 4,000 萬美元的 B 輪資金籌措，這就是該領域取得進展的顯著例證。此融資將用於推進創新多巴胺拮抗劑地多潘立酮的 II 期臨床試驗，該藥物旨在緩解慢性症狀，且不會產生現有治療方法的副作用。這項重大研發投資凸顯了業界致力於加速將先進的胃麻痺治療藥物推向市場的決心。

同時，全球糖尿病盛行率的不斷上升是推動胃麻痺治療需求成長的根本因素，形成了一個龐大且持續成長的目標患者群體。隨著糖尿病診斷數量的增加，相關消化器官系統併發症的發生率也相應上升，因此，持續的治療性介入以控制排放延遲至關重要。例如，美國疾病管制與預防中心（CDC）在2024年5月報告稱，美國各年齡層中約有3,840萬人患有糖尿病，凸顯了主要市場中存在大量高危險群。患者群體的擴大直接轉化為已獲已通過核准治療方法的商業性化應用。例如，Evoke Pharma在2024年11月宣布，其鼻噴劑「GIMOTI」第三季淨銷售額達到270萬美元，較去年同期成長70%。

市場挑戰

針對藥品安全性和有效性的嚴格法規環境，對全球糖尿病胃麻痺治療市場的擴張構成了重大障礙。監管機構強制執行嚴格的臨床試驗標準，尤其旨在降低長期使用現有胃動力增強劑所帶來的嚴重風險。這些對安全性數據的嚴格要求導致研發週期漫長且成本高昂，常常造成產品在後期臨床試驗中失敗。因此，在缺乏確鑿安全性證據的情況下謹慎核准新藥，會形成准入壁壘，阻礙創新，限制新治療方法的引入。這迫使市場依賴存在固有風險的老藥。

因此，這些監管限制縮小了治療方法選擇範圍，從而限制了市場的商業性潛力，使特定患者群體（遭受嚴重痛苦）的治療選擇更加有限。近期發表的盛行率數據清晰地表明，這種疾病帶來的巨大負擔與核准治療方案的匱乏之間存在著巨大的差距。根據美國胃腸病學會預測，到2025年，美國胃麻痺症的盛行率將達到每10萬人中約21-24例，其中女性患者佔絕大多數。這項數據凸顯了龐大的未開發市場的存在，由於監管核准的延誤，該市場仍未得到充分滿足，直接阻礙了產生收入和整體市場發展。

市場趨勢

一個值得關注的趨勢是內視鏡胃鏡（GPOEM）的應用日益普及。這表明，對於其他治療方法無效的胃麻痺病例，治療方向正從根本上轉向微創介入。該手術透過機械方式改善幽門痙攣，促進排放，為藥物治療無效的患者提供了一種新的選擇。 GPOEM之所以受到醫療專業人員的青睞，是因為與傳統外科手術相比，它可能提供更持久的症狀緩解。發表於2025年1月《胃腸內視鏡》（Gastrointestinal Endoscopy）雜誌的Meta分析（研究論文：《內視鏡胃麻痺在不同病因中的療效和安全性》）報告稱，其總體臨床成功率達65%，尤其是在糖尿病相關性胃麻痺方面。

同時，隨著胃電刺激療法在難治性病例中的應用範圍不斷擴大，市場也在持續成長，惠及先前未被視為器械治療適用人群的患者群體。這一趨勢包括探索神經刺激療法在慢性噁心嘔吐患者中的應用，即使這些患者的排放率正常。製造商正優先進行臨床試驗以驗證此擴展適應症。例如，2025年6月，Entera Medical在一份題為「慢性噁心的新希望：Entera Medical啟動NAVIGATE試驗」的新聞稿中宣布，已啟動一項至少招募148名受試者的III期臨床試驗，旨在評估該療法在這一日益成長的患者群體中的安全性和有效性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：糖尿病胃排空排放治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（2 級（補償胃麻痺），3 級（胃功能不全））
    • 藥物分類（胃動力興奮劑、止吐藥、抗組織胺藥物、其他）
    • 給藥途徑（口服、注射、鼻內）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美糖尿病排放胃排空治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲糖尿病胃排空排放治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區糖尿病胃排空排放治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲糖尿病胃排空排放治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲糖尿病胃排空排放治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球糖尿病胃排空排放治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • ANI Pharmaceuticals, Inc.
  • Evoke Pharma
  • Janssen Pharmaceutica NV
  • Teva Pharmaceuticals Inc.
  • Pfizer Inc.
  • Salix Pharmaceuticals, Inc.
  • Allergan Plc.
  • Novartis AG
  • SCHWITZ BIOTECH
  • Wellona Pharmaceutical Private Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17285

The global market for diabetic gastroparesis treatments is projected to expand from USD 3.03 Billion in 2025 to USD 3.74 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 3.57%. This market includes pharmacological interventions like prokinetics and antiemetics, alongside surgical devices and procedures, all aimed at managing delayed gastric emptying in diabetic patients. A key driver for this growth is the increasing worldwide prevalence of diabetes, which in turn leads to a higher occurrence of gastrointestinal issues requiring effective symptom management. For example, in 2024, the International Diabetes Federation reported that approximately 589 million adults globally were living with diabetes, forming a large patient demographic prone to such long-term complications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.03 Billion
Market Size 2031USD 3.74 Billion
CAGR 2026-20313.57%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

However, the market's growth faces a notable obstacle due to the rigorous regulatory environment governing drug safety and efficacy. Many current treatments are associated with severe adverse effects, compelling regulatory bodies to enforce stringent clinical trial standards and issue safety warnings for both new and existing medications. This strict oversight creates a significant barrier to market entry, extending product development timelines and limiting the approval of innovative therapeutic agents, consequently narrowing the range of treatment options available to healthcare providers and patients.

Market Driver

A significant driver for the market's advancement is the strong clinical pipeline and the ongoing development of novel therapeutics, as pharmaceutical companies strive to create safer alternatives to conventional prokinetic agents. Manufacturers are focusing on formulating new chemical entities to reduce cardiac and neurological risks linked to older medications like metoclopramide, thereby addressing persistent regulatory safety issues. A notable example of this progress is CinDome Pharma's May 2024 announcement of securing a $40 million Series B financing extension to progress Phase 2 clinical trials for deudomperidone, an innovative dopamine antagonist designed to offer chronic symptom relief without the side effects of current treatments. This substantial investment in development underscores the industry's dedication to expediting the launch of advanced pharmacological solutions for gastroparesis management.

Concurrently, the rising global prevalence of diabetes mellitus is a foundational element driving the demand for gastroparesis treatments, establishing a large and expanding target patient demographic. As diabetes diagnoses increase, the incidence of associated gastrointestinal complications also rises proportionally, mandating ongoing therapeutic interventions to manage delayed gastric emptying. For instance, in May 2024, the Centers for Disease Control and Prevention reported that about 38.4 million people of all ages in the United States were living with diabetes, highlighting the vast number of at-risk individuals in key markets. This growing patient base directly translates into higher commercial adoption of approved therapies; for example, Evoke Pharma stated in November 2024 that net product sales for its nasal formulation, GIMOTI, reached $2.7 million in the third quarter, marking a 70% increase year-over-year.

Market Challenge

The rigorous regulatory environment surrounding drug safety and efficacy presents a substantial impediment to the expansion of the Global Diabetic Gastroparesis Treatment Market. Regulatory authorities mandate stringent clinical trial standards to reduce severe risks, particularly those linked to the prolonged use of current prokinetic agents. This demanding requirement for safety data necessitates lengthy and expensive development phases, frequently resulting in product failures during late-stage trials. As a result, the hesitance to approve new agents without conclusive safety evidence establishes a barrier to entry that curtails innovation and restricts the introduction of novel therapies, forcing the market to depend on older medications with inherent risks.

This regulatory constraint consequently limits the market's commercial potential by reducing the array of available treatments for a well-defined patient population experiencing significant suffering. The discrepancy between the considerable burden of the disease and the scarcity of approved therapeutic alternatives is evident in recent prevalence figures. The American Gastroenterological Association reported that in 2025, gastroparesis affected approximately 21 to 24 per 100,000 individuals in the United States, with women constituting the majority of cases. This statistic underscores a significant addressable market that continues to be underserved due to the slow rate of regulatory approvals, thereby directly hindering revenue generation and overall market growth.

Market Trends

A notable trend is the growing adoption of Gastric Peroral Endoscopic Myotomy (GPOEM), signifying a fundamental shift towards minimally invasive interventions for cases of gastroparesis that are resistant to other treatments. This procedure works by mechanically addressing pyloric spasms to improve gastric emptying, providing an alternative for patients who do not respond to pharmacological management. Medical professionals are increasingly employing GPOEM due to its potential to offer more lasting symptom relief compared to conventional surgical approaches. As published in Gastrointestinal Endoscopy in January 2025, a meta-analysis of 982 patients, detailed in the study 'Efficacy and safety of gastric peroral endoscopic myotomy across different etiologies of gastroparesis,' reported a pooled clinical success rate of 65% specifically for diabetes-related gastroparesis.

Concurrently, the market is expanding through the broader application of Gastric Electrical Stimulation for refractory cases, reaching patient groups previously not considered for device-based therapies. This trend involves exploring neurostimulation for individuals experiencing chronic nausea and vomiting who nonetheless have normal gastric emptying rates. Manufacturers are prioritizing clinical trials to confirm this expanded indication. For example, Enterra Medical announced in June 2025, via their press release 'New Hope for Chronic Nausea, Enterra Medical Begins NAVIGATE Study,' the commencement of a pivotal trial enrolling a minimum of 148 subjects to evaluate the safety and effectiveness of this approach within this growing patient population.

Key Market Players

  • ANI Pharmaceuticals, Inc.
  • Evoke Pharma
  • Janssen Pharmaceutica N.V
  • Teva Pharmaceuticals Inc.
  • Pfizer Inc.
  • Salix Pharmaceuticals, Inc.
  • Allergan Plc.
  • Novartis AG
  • SCHWITZ BIOTECH
  • Wellona Pharmaceutical Private Limited

Report Scope

In this report, the Global Diabetic Gastroparesis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Gastroparesis Treatment Market, By Type

  • Grade 2(Compensated Gastroparesis)
  • Grade 3(Gastric Failure)

Diabetic Gastroparesis Treatment Market, By Drug Class

  • Gastroprokinetic Agents
  • Antiemetic Agents
  • Antihistamines
  • Others

Diabetic Gastroparesis Treatment Market, By Route of Administration

  • Oral
  • Parenteral
  • Nasal

Diabetic Gastroparesis Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Diabetic Gastroparesis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Gastroparesis Treatment Market.

Available Customizations:

Global Diabetic Gastroparesis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diabetic Gastroparesis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Grade 2(Compensated Gastroparesis), Grade 3(Gastric Failure))
    • 5.2.2. By Drug Class (Gastroprokinetic Agents, Antiemetic Agents, Antihistamines, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Nasal)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Diabetic Gastroparesis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Class
    • 6.2.3. By Route of Administration
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diabetic Gastroparesis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Diabetic Gastroparesis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Diabetic Gastroparesis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Distribution Channel

7. Europe Diabetic Gastroparesis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diabetic Gastroparesis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Diabetic Gastroparesis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Diabetic Gastroparesis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Diabetic Gastroparesis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Diabetic Gastroparesis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Diabetic Gastroparesis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diabetic Gastroparesis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Diabetic Gastroparesis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Diabetic Gastroparesis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Diabetic Gastroparesis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Diabetic Gastroparesis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Diabetic Gastroparesis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diabetic Gastroparesis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Diabetic Gastroparesis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Diabetic Gastroparesis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel

10. South America Diabetic Gastroparesis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diabetic Gastroparesis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Diabetic Gastroparesis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Diabetic Gastroparesis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diabetic Gastroparesis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ANI Pharmaceuticals, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Evoke Pharma
  • 15.3. Janssen Pharmaceutica N.V
  • 15.4. Teva Pharmaceuticals Inc.
  • 15.5. Pfizer Inc.
  • 15.6. Salix Pharmaceuticals, Inc.
  • 15.7. Allergan Plc.
  • 15.8. Novartis AG
  • 15.9. SCHWITZ BIOTECH
  • 15.10. Wellona Pharmaceutical Private Limited

16. Strategic Recommendations

17. About Us & Disclaimer